Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(2.14)
# 2,807
Out of 4,886 analysts
16
Total ratings
58.33%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $30 → $42 | $27.21 | +54.36% | 2 | Jul 9, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $21.45 | +105.13% | 1 | Jun 26, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Equal-Weight | $13 → $12 | $10.13 | +18.52% | 6 | May 28, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $9.26 | -13.61% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $52.25 | +70.33% | 1 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $26 | $8.50 | +205.88% | 2 | May 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $8.27 | +299.03% | 2 | Feb 28, 2025 |
Kiniksa Pharmaceuticals International,
Jul 9, 2025
Maintains: Overweight
Price Target: $30 → $42
Current: $27.21
Upside: +54.36%
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $21.45
Upside: +105.13%
iTeos Therapeutics
May 28, 2025
Downgrades: Equal-Weight
Price Target: $13 → $12
Current: $10.13
Upside: +18.52%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $9.26
Upside: -13.61%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $52.25
Upside: +70.33%
Arcus Biosciences
May 7, 2025
Maintains: Overweight
Price Target: $29 → $26
Current: $8.50
Upside: +205.88%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $8.27
Upside: +299.03%